About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker RVMD · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 6, 2026Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel…
NCT07805954 · Pancreatic Cancer, Pancreatic Cancer Metastatic
daraxonrasib, gemcitabine
RVMD
Revolution Medicines, Inc.
Phase 3Recruiting400Mar 2029Registry ↗
Nov 6, 2026Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice a…
NCT07621718 · Pancreatic Cancer, Pancreatic Cancer Metastatic
Zoldonrasib, Placebo
RVMD
Revolution Medicines, Inc.
Phase 3Recruiting670Dec 30, 2028Registry ↗
Nov 6, 2026Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784 · NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Can…
daraxonrasib, docetaxel
RVMD
Revolution Medicines, Inc.
Phase 3Recruiting590Dec 1, 2027Registry ↗
Nov 4, 2026Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Li…
NCT07777822 · NSCLC, Non-small Cell Lung Cancer
zoldonrasib, Placebo
RVMD
Revolution Medicines, Inc.
Phase 3Recruiting430Oct 2029Registry ↗
Nov 4, 2026Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338 · Advanced Solid Tumors, Metastatic Solid Tumors
Daraxonrasib, Elironrasib
RVMD
Revolution Medicines, Inc.
Phase 1/2Recruiting370May 2029Registry ↗
Oct 23, 2026Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232 · Pancreatic Cancer, PDAC
daraxonrasib
RVMD
Revolution Medicines, Inc.
Phase 3Recruiting500May 10, 2029Registry ↗
Oct 19, 2026Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221 · Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated…
RMC-6291, RMC-6236
RVMD
Revolution Medicines, Inc.
Phase 1/2Recruiting616Jun 2027Registry ↗
Oct 2, 2026Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pa…
NCT07491445 · Pancreatic Cancer, Pancreatic Cancer Metastatic
daraxonrasib, gemcitabine
RVMD
Revolution Medicines, Inc.
Phase 3Recruiting900Jun 2028Registry ↗
Sep 22, 2026Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
NCT06445062 · Colorectal Cancer, CRC
RMC-6236, mFOLFOX6 regimen
RVMD
Revolution Medicines, Inc.
Phase 1/2Recruiting1,130Sep 30, 2028Registry ↗
Sep 22, 2026Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With…
NCT06128551 · Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer
Elironrasib, Daraxonrasib
RVMD
Revolution Medicines, Inc.
Phase 1/2Recruiting534Dec 2028Registry ↗
Sep 17, 2026Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
NCT07349537 · Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
RMC-5127, daraxonrasib
RVMD
Revolution Medicines, Inc.
Phase 1Recruiting574Apr 2028Registry ↗
Sep 1, 2026Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Ade…
NCT07573215 · PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
daraxonrasib
RVMD
Revolution Medicines, Inc.
—Approved for marketing——Registry ↗
Jun 3, 2026Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06040541 · Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
RMC-9805, RMC-6236
RVMD
Revolution Medicines, Inc.
Phase 1Recruiting604Dec 31, 2026Registry ↗
Jun 2, 2026Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic…
NCT06625320 · Pancreatic Cancer, PDAC
RMC-6236, Gemcitabine
RVMD
Revolution Medicines, Inc.
Phase 3Active, not recruiting500Jun 2026Registry ↗
May 15, 2026Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C…
NCT05462717 · Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
RMC-6291
RVMD
Revolution Medicines, Inc.
Phase 1Active, not recruiting222Mar 31, 2027Registry ↗
May 15, 2026Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT05379985 · Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
RMC-6236
RVMD
Revolution Medicines, Inc.
Phase 1/2Recruiting754May 31, 2027Registry ↗
Jan 6, 2026Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure…
NCT05054725 · Non-Small Cell Lung Cancer
RMC-4630, Sotorasib
RVMD
Revolution Medicines, Inc.
Phase 2Completed47Jul 3, 2024Registry ↗
Apr 15, 2025Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
NCT04774952 · Solid Tumors
RMC-5552
RVMD
Revolution Medicines, Inc.
Phase 1Completed58May 6, 2024Registry ↗
Jun 26, 2023Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv…
NCT03989115 · Solid Tumor
RMC-4630, Cobimetinib
RVMD
Revolution Medicines, Inc.
Phase 1/2Completed113Feb 8, 2022Registry ↗
Sep 1, 2022Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
NCT03634982 · Solid Tumors
RMC-4630
RVMD
Revolution Medicines, Inc.
Phase 1Unknown133Mar 31, 2023Registry ↗

20 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:50 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances